Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study

Inclusion Criteria:

1. Diagnosed cT\>=3 or cN+ stage rectal cancer by pelvic MRI or enhanced CT scan;
2. Pathological proved primary rectal adenocarcinoma;
3. Recieved full-cource radiation or more than 3 cycles of chemotherapy before surgery;
4. Recieved radical tumor resection by TME surgery.

Exclusion Criteria:

1. Diganosed with any distant metastasis disease or locally unresectable disease before neoadjuvant treatment or surgery;
2. Recieved local resection surgery (R2 resection) or postoperative pathology confirmed positive surgical margins (R1 resection);
3. Patients who died due to intra- or post-operative complications;
4. Patient who die or relapse within 30 days after surgery;
5. Patients who had a prior history of malignancy within 5 years before surgery;
6. Patients who were loss of follow-up or had inadequate clinical data.